• Waleed Mohamed Abdulkhair Researcher, General Department of Basic Medical Sciences, Microbiology Department, National Organization for Drug Control and Research
  • Walaa Said Abdel-all Associate professor, General Department of Basic Medical Sciences, Microbiology Department, National Organization for Drug Control and Research
  • Rehab Hasan Bahy Researcher, General Department of Basic Medical Sciences, Microbiology Department, National Organization for Drug Control and Research


Objective: This study aims to control type 2 of diabetes mellitus by a hypoglycemic substance that extensively produced by Streptomyces bacteria. The antidiabetic action of this substance depends on prevention of starch hydrolysis and then the liberation of glucose monomers via an inhibition of α-glucosidase as one of starch hydrolyzing enzymes.

Methods: The strains of marine actinomycetes were isolated on starch nitrate agar, and then qualitatively and quantitatively screened to prevent starch hydrolysis. The most potent strain was identified by classical and genetical methods. The genetic improvement of the most potent strain was carried out by using UV radiations at different exposure periods per second. The optimization of environmental conditions was studied to obtain the maximum activity of the α-glucosidase inhibitory protein, which purified and electrically separated to determine its molecular weight.

Results: Among 55 marine actinomycetes, only 7 strains were found have antidiabetic activity. This activity was assayed spectrophotometrically at 400 nm, where p-nitrophenyl-α-d-glucopyranoside and acarbose were used as a substrate and a positive control respectively. The most potent strain which marked as AD-7 was identified as Streptomyces coelicolor, which exposed to the genetic improvement using UV radiations to obtain a highly activity of an inhibitory protein at 10 s of the exposure period. The activity and stability continued for 5 d at 37 °C. The maximum activity and stability of an improved inhibitory protein were obtained with optimization of environmental conditions included inoculum size (106 cfu/ml/300 µl), incubation period (14 d), agitation speed (160 rpm), incubation temperature (30 °C), and pH (8.5). An inhibitor was purified and separated at 34 KDa.

Conclusion: Alpha-glucosidase inhibitory protein as a powerful hypoglycemic agent was extracted from the filtrate of S. coelicolor. The mutant strain of the latter had been produced most active and stable inhibitory protein, which prevents the starch hydrolysis via an inhibition of α-glucosidase enzyme for 5 d at 37 °C.

Keywords: Antidiabetic agents, Diabetes mellitus, Enzyme inhibitors, Physical mutagenesis, Starch hydrolysis


Download data is not yet available.


1. West IC. Radicals and oxidative stress in diabetes. Diabetes Med 2000;17:171-80.
2. Chakrabarti R, Rajagopalan R. Diabetes and insulin resistance associated disorders: disease and the therapy. Curr Sci 2002;83:1533-8.
3. Norman P. Diabetes pipeline: intense activity to meet unmet need report-overview. 2nd ed. Massachusetts (USA): Cambridge Healthtech Institute; 2010.
4. Bailey CJ, Day C. Antidiabetic drugs. Br J Cancer 2003;10:128-36.
5. De la Monte SM. Type 3 diabetes is sporadic alzheimer's disease. Eur Neurol Pharmacol 2014;24:1954-60.
6. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009;32:1335-43.
7. Bhosale UP, Hallale BV. Gamma radiation-induced mutations in black gram (Vigna mungo L. Hepper). Asian J Plant Sci Res 2011;1:96-100.
8. Subramanian R, Asmawi AZ, Sadikun A. In vitro alpha-glucosidase and alpha-amylase enzyme inhibitory effects of Andrographis paniculata extract and andrographolide. Ambrose Bierce Project 2008;55:391-8.
9. Fatmawati S, Shimizu K, Kondo R, Ganoderol B. A potent α-glucosidase inhibitor isolated from the fruiting body of Ganoderma lucidum. Phytomedicine 2011;18:1053-5.
10. Hanefeld M, Schaper F. The role of alpha-glucosidase inhibitors (Acarbose). In: Mogensen CE, editor. Pharmacotherapy of diabetes: new developments. 2nd ed. Springer: Boston MA; 2007. p. 143-52.
11. Chiasson JL, Robert GJ, Ramon G, Hanefeld M, Karasik A, Laakso M, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance the STOP-NIDDM trial. J Am Med Association 2003;290:486-94.
12. Schmidit DD, Frommer W, Junge B, Muller L, Wingender W, Truscheit E, et al. α-glucosidase inhibitors: new complex oligosaccharides of microbial origin. Naturwissenschaften 1977;64:535–6.
13. McGown J. Out of Africa: Mysteries of access and benefit sharing. 2nd ed. Washington (USA): The Edmonds Institute; 2006.
14. De Melo EB, Gomes ADS, Carvalho I. α-and β-glucosidase inhibitors: chemical structure and biological activity. Tetrahedron 2006;62:10277–302.
15. Kameda Y, Asano N, Yoshikawa M, Matsui K. Valienamine as an α-glucosidase inhibitor. J Antibiot 1980;33:1575–6.
16. Mahmud T. The C7 N aminocyclitol family of natural products. Nat Prod Rep 2003;20:137–66.
17. Truscheit E, Frommer W, Junge B, Muller L, Schmidt DD, Wingender W. Chemistry and biochemistry of microbial-glucosidase inhibitors. Angewandte Chem 1981;20:744–61.
18. Yokose K, Ogawa K, Sano T, Watanabe K, Maruyama HB, Suhara Y. New alpha-amylase inhibitor, trestatins. I. isolation, characterization and biological activities of trestatins A, B and C. J Antibiot 1983;36:1157–65.
19. Yokose K, Ogawa M, Ogawa K. New α-amylase inhibitor, trestatins III: structure determination of new trestatin components ro 09-0766, Ro 090767 and Ro 09-0768. J Antibiot 1984;37:182–6.
20. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a cochrane systematic review and meta-analysis. Diabetes Care 2005;28:154-63.
21. Morshed MA, Haque A, Rokeya B, Ali L. Anti-Hyperglycemic and lipid-lowering effect of Terminalia arjuna bark extract on streptozotocin-induced type 2 diabetic model rats. Int J Pharm Pharm Sci 2011;3:449-53.
22. Lamba HS, Bhargava CS, Thakur M, Bhargava S. Alpha glucosidase and aldolase reductase inhibitory activity in vitro and antidiabetic activity in vivo of Tribulus terrestris L. (DUNAL). Int J Pharm Pharm Sci 2011;3:270-2.
23. Upwar N, Patel R, Waseem N, Mahobia NK. Hypoglycemic effect of methanolic extract of Berberis aristata DC stem on normal and streptozotocin-induced diabetic rats. Int J Pharm Pharm Sci 2011;3:222-4.
24. Waksman SA. The actinomyces: antibiotics of actinomycetes. 2nd ed. USA: The Williams and Wilkins company; 1961.
25. Anam K, Widharna RM, Kusrini D. α-glucosidase inhibitor activity of Terminalia species. Int J Pharmacol 2009;5:277-80.
26. Shirling EB, Gottlieb D. Methods for characterization of Streptomyces species. Int J Syst Evol Microbiol 1996;16:313-40.
27. Pitcher DG, Saunder NA, Own RJ. Rapid extraction of bacterial genomic DNA with guanidium thiocyanate. Lett Appl Microbiol 1989;8:151-6.
28. Weisburg WG, Barns SM, Pelletie DA, Lane DJ. 16S ribosomal DNA amplification for phylogenetic study. J Bacteriol 1991;173:697-703.
29. Lowery OH, Rosebrough J, Farr AL, Randall RJ. Protein measurements with the folin phenol reagent. J Biol Chem 1951;193:265-75.
30. Dale JW, Smith JT. The purification and properties of the β-lactamase specified by the resistance factor R-1818 in E coli and Proteus mirabilis. Biochem J 1971;123:493-500.
31. Andrews P. Estimation of the molecular weight of proteins by sephadex gel filtration. Biochem J 1964;91:222-3.
32. Blackshear PJ. Systems for polyacrylamide gel electrophoresis. Methods Enzymol 1984;104:237-55.
33. Zhang L, Rong A, Wang J, Sun N, Zhang S, Hu J, et al. Exploring novel bioactive compounds from marine microbes. Curr Opin Microbiol 2005;8:276–81.
34. Imada C. Enzyme inhibitors and other bioactive compounds from marine actinomycetes. Antonie Van Leeuwenhoek 2005;87:59-63.
35. Lazzarini A, Cavaletti L, Toppo G, Marinelli F. Rare genera of actinomycetes as potential producers of new antibiotics. Antonie Van Leeuwenhoek 2000;78:399-405.
36. Siva KK, Sahu MK, Kathiresan K. Isolation of actinomycetes from the mangrove environment of the South-East Coast of India. Ecol Environ Conserv 2005;11:355-7.
37. Ganesan S, Raja S, Sampathkumar P, Sivakumar K, Thangaradjou T. Isolation and screening of -glucosidase enzyme inhibitor producing marine actinobacteria. Afr J Microbiol Res 2011;5:3437-245.
38. Imada C, Simidu U. Culture conditions for an -amylase inhibitor-producing marine actinomycetes and production of the inhibitor Amylostreptin”. Nippon Suisan Gakk 1992;58:2169-74.
39. Pridham TG, Lyons JR. Streptomyces albus (Rossi-Doria) Waksman and Henric: a taxonomic study of strains labelled Streptomyces albus. J Bacteriol 1961;81:431-41.
40. Bentley SD, Chater KF, Cerdeno-Tarraga AM, Challis GL, Thomson NR, James K, et al. Complete genome sequence of the model actinomycete Streptomyces coelicolor A3. Nature 2002;417:141-7.
41. Adepu KK. UV mutagenesis treatment for improved production of endoglucanase and β-Glucosidase from newly isolated thermotolerant actinomycetes, Streptomyces gresioaurantiacus. Bioresour Bioprocess 2015;2:22.
42. Chand P, Aruna A, Maqsood AM, Rao LV. Novel mutation method for increased cellulase production. J Appl Microbiol 2005;98:318–23.
43. Fei R, Long C, Shuangli X, Qunyi T. Enhanced acarbose production by Streptomyces M37 using a two-stage fermentation strategy. Pub Lib Sci One 2017;12:1-11.
44. Zhuge X, Liu L, Shin HD, Li J, Du G. Improved propionic acid production from glycerol with metabolically engineered Propionibacterium jensenii by integrating fed-batch culture with a pH-shift control strategy. J Bioresour Technol 2014;152:519–25.
212 Views | 529 Downloads
How to Cite
Abdulkhair, W. M., W. S. Abdel-all, and R. H. Bahy. “GENETIC IMPROVEMENT OF ANTIDIABETIC ALPHA-GLUCOSIDASE INHIBITOR PRODUCING STREPTOMYCES SP”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 10, no. 5, May 2018, pp. 77-84, doi:10.22159/ijpps.2018v10i5.25338.
Original Article(s)